Evommune Statistics

Total Valuation

Evommune has a market cap or net worth of $921.35 million. The enterprise value is $774.21 million.

Market Cap	921.35M
Enterprise Value	774.21M

Important Dates

The next estimated earnings date is Thursday, June 11, 2026, after market close.

Earnings Date	Jun 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Evommune has 36.02 million shares outstanding. The number of shares has increased by 306.86% in one year.

Current Share Class	36.02M
Shares Outstanding	36.02M
Shares Change (YoY)	+306.86%
Shares Change (QoQ)	+1,179.99%
Owned by Insiders (%)	2.59%
Owned by Institutions (%)	41.24%
Float	19.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	70.87
Forward PS	n/a
PB Ratio	3.92
P/TBV Ratio	4.48
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	59.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.57, with a Debt / Equity ratio of 0.01.

Current Ratio	8.57
Quick Ratio	8.33
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-11,581.57

Financial Efficiency

Return on equity (ROE) is -54.42% and return on invested capital (ROIC) is -39.64%.

Return on Equity (ROE)	-54.42%
Return on Assets (ROA)	-33.67%
Return on Invested Capital (ROIC)	-39.64%
Return on Capital Employed (ROCE)	-39.16%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	$270,833
Profits Per Employee	-$1.43M
Employee Count	48
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	25.47
200-Day Moving Average	n/a
Relative Strength Index (RSI)	49.89
Average Volume (20 Days)	275,222

Short Selling Information

The latest short interest is 3.46 million, so 9.60% of the outstanding shares have been sold short.

Short Interest	3.46M
Short Previous Month	3.06M
Short % of Shares Out	9.60%
Short % of Float	17.65%
Short Ratio (days to cover)	10.14

Income Statement

In the last 12 months, Evommune had revenue of $13.00 million and -$68.87 million in losses. Loss per share was -$11.22.

Revenue	13.00M
Gross Profit	13.00M
Operating Income	-81.07M
Pretax Income	-68.87M
Net Income	-68.87M
EBITDA	-79.68M
EBIT	-81.07M
Loss Per Share	-$11.22

Full Income Statement

Balance Sheet

The company has $149.20 million in cash and $2.06 million in debt, giving a net cash position of $147.14 million or $4.09 per share.

Cash & Cash Equivalents	149.20M
Total Debt	2.06M
Net Cash	147.14M
Net Cash Per Share	$4.09
Equity (Book Value)	205.57M
Book Value Per Share	6.52
Working Capital	135.57M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$76.44 million and capital expenditures -$235,000, giving a free cash flow of -$76.68 million.

Operating Cash Flow	-76.44M
Capital Expenditures	-235,000
Depreciation & Amortization	1.39M
Net Borrowing	-531,000
Free Cash Flow	-76.68M
FCF Per Share	-$2.13

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-623.62%
Pretax Margin	-529.77%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Evommune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-306.86%
Shareholder Yield	-306.86%
Earnings Yield	-7.47%
FCF Yield	-8.32%

Analyst Forecast

The average price target for Evommune is $43.88, which is 71.54% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$43.88
Price Target Difference	71.54%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	84.66%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Evommune has an Altman Z-Score of 15.99 and a Piotroski F-Score of 1.

Altman Z-Score	15.99
Piotroski F-Score	1